These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24377585)

  • 1. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
    Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
    Wei GL; Huang XE; Huo JG; Wang XN; Tang JH
    Asian Pac J Cancer Prev; 2013; 14(5):2703-6. PubMed ID: 23803018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
    Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
    J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
    Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
    Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study.
    Zhang DS; Jin Y; Luo HY; Wang ZQ; Qiu MZ; Wang FH; Li YH; Xu RH
    Br J Cancer; 2015 Jan; 112(2):266-70. PubMed ID: 25474247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J
    Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers.
    Qian T; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(11):4791-5. PubMed ID: 26107242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs.
    Lu YY; Huang XE; Xu L; Liu DG; Cao J; Wu XY; Liu J; Xiang J
    Asian Pac J Cancer Prev; 2013; 14(3):2005-8. PubMed ID: 23679308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
    Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
    J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
    Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
    Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
    Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.
    Lau DH; Moon J; Davies AM; Sanborn RE; Hirsch FR; Franklin WA; Ruzich JC; Redman MW; Gandara DR
    Clin Lung Cancer; 2013 Jul; 14(4):351-5. PubMed ID: 23415808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
    Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
    J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
    Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
    J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
    Russo F; Bearz A; Pampaloni G;
    BMC Cancer; 2008 Jul; 8():216. PubMed ID: 18667090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
    Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
    Zhang RX; Cai DY; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.